Headlines

AbbVie (ABBV) to invest USD 380mln in north Chicago to further expand active pharmaceutical ingredient manufacturing in the US; construction to begin in spring 2026, operational by 2029

Newsquawk Staff ·

AbbVie (ABBV) to invest USD 380mln in north Chicago to further expand active pharmaceutical ingredient manufacturing in the US; construction to begin in spring 2026, operational by 2029.

What it means

AbbVie's announcement of a significant investment in active pharmaceutical ingredient manufacturing signals a strategic commitment to strengthening its domestic production capabilities. This move not only reflects the company's long-term growth strategy but also aligns with broader trends in reshoring production, which may enhance its supply chain resilience and potentially improve profit margins in the future.

Related headlines